Revolution Medicines to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

Rhea-AI Summary

Revolution Medicines (Nasdaq: RVMD) will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference from June 8-11, 2021. CEO Mark A. Goldsmith will engage in a fireside chat on June 9, 2021, at 3:00 p.m. Eastern Time. Interested individuals can access the live webcast through the events page on Revolution Medicines’ website, with a replay available for 14 days post-conference. The company focuses on precision oncology, developing targeted therapies for RAS-addicted cancers, including RMC-6291 and RMC-6236.

REDWOOD CITY, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in the upcoming Goldman Sachs 42^nd Annual Global Healthcare Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside chat at the event.

Details of these company’s participation are as follows:

• Goldman Sachs 42^nd Annual Global Healthcare Conference
  Conference Date: June 8-11, 2021
  Fireside Chat Time/Date: 3:00 p.m. Eastern on Wednesday, June 9, 2021
  Format: Virtual conference; webcast available

To access the live webcast of the fireside chat, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. A replay of the webcast will be available on the “Events & Presentations” page of the Revolution Medicines’ website for at least 14 days following the conference.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.

The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845.

FAQ

What is the date of the Goldman Sachs 42nd Annual Global Healthcare Conference for Revolution Medicines?

The conference will take place from June 8-11, 2021.

When will Revolution Medicines' CEO participate in a fireside chat during the Goldman Sachs conference?

The fireside chat is scheduled for June 9, 2021, at 3:00 p.m. Eastern Time.

How can I access the live webcast of Revolution Medicines' fireside chat?

You can access the live webcast on the 'Events & Presentations' page of Revolution Medicines' website.

What is the focus of Revolution Medicines' research and development?

Revolution Medicines focuses on developing targeted therapies for RAS-addicted cancers.

What are some of the RAS(ON) Inhibitors being developed by Revolution Medicines?

Some RAS(ON) Inhibitors under development include RMC-6291 and RMC-6236.